HCC Clinical Trial
Official title:
Statin With Palliative Therapy for HCC
Statin is a preventive medicine for hepatitis B and hepatitis C which decreases the risk turning into liver cancer,however, the investigators also discovered that patients taking Statin live longer than patients who didn't take Statin in the incidence of liver cancer death cases.
Most liver cancer patients did not accept the cure as the main objective of the treatment
after diagnosis because they choose alternative therapies palliative based, such as hepatic
arterial chemoembolization, chemotherapy and radiation therapy.
Statin is a preventive medicine for hepatitis B and hepatitis C which decreases the risk
turning into liver cancer, yet the clinical effect for Statin is still unknown.
In a previous study of 20,220 liver cancer patients in health care database, the
investigators discovered that patients taking Statin live longer than patients who didn't
take Statin in the incidence of liver cancer death cases.
This study is a continuation of previous health insurance database studies for clinical
trials to verify whether Statin could prolong disease-free survival role for palliative
treatment of liver cancer.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05458115 -
Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
|
||
| Not yet recruiting |
NCT05022628 -
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
|
Phase 4 | |
| Enrolling by invitation |
NCT02256514 -
Open Label Trial of Immunotherapy for Advanced Liver Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06434480 -
SBRT in HCC With Oligoprogression on Atezo-Bev
|
N/A | |
| Completed |
NCT04542837 -
The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT05025592 -
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
|
||
| Completed |
NCT04172506 -
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05840133 -
Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
|
||
| Not yet recruiting |
NCT06024252 -
Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
|
||
| Not yet recruiting |
NCT02715492 -
Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.
|
Phase 3 | |
| Completed |
NCT02985034 -
Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT
|
N/A | |
| Not yet recruiting |
NCT06069947 -
SALT for Liver Cirrhosis With HCC
|
N/A | |
| Recruiting |
NCT05581004 -
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Suspended |
NCT02935478 -
Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation
|
N/A | |
| Recruiting |
NCT05592171 -
Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC
|
N/A | |
| Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
| Recruiting |
NCT05544253 -
Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06184152 -
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
|
||
| Completed |
NCT02675920 -
A Study of HCC High Risk Group Using Two Surveillance Tools
|
||
| Completed |
NCT02833298 -
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
|
N/A |